Biomedical subjects

H Maderbacher

Publications and source records attributed to H Maderbacher.

3 recordsLinked to original sources

PubMed2002

[Therapy of Helicobacter pylori infection: "Who to treat, how to treat?"].

Seventeen years after detection of Helicobacter pylori as the pathogenetic factor in a variety of gastroduodenal diseases, current treatment options are about 90% effective in eradicating the bacteria and thereby curing the affiliated disorders. In 1987 successful therapy has been shown to reduce relapse rates of duodenal and gastric ulcers dramatically and clinicians all over the world started to perform a still ongoing vast number of trials searching for the most effective first--and in case of failure, second line-treatment options. The results of these trials led to strictly evidence based and generally accepted guidelines formulated by Consensus Reports. The main questions "who to treat" and "how to treat" can be answered by using the categories "strongly recommended indications", "advisable indications" that leave some space for individual decisions, and consideration of first and second time eradication therapies together as a package. Treatment has become simple: three drugs, twice daily for one week. All available protone pump inhibitors (PPI) have been shown to be effective and presently there is only a few antibiotic agents used in combination and defined dose, proven to ensure treatment success. The future will encounter clinicians with problems concerning patient compliance, antibiotic resistance and more effective second and even third line therapies. This paper will focus on two subjects: indications ("who to treat") and evidence-based eradication regimens ("how to treat") in a reasonable setting close to everyday clinical practice.

Anti-Bacterial Agents↗

PubMed1986

[Uricosuric action of a new beta receptor blocker-diuretic drug combination].

The influence of a once daily dose of 200 mg celiprolol alone and in combination with 12.5 mg chlorthalidone on uric acid and electrolyte metabolism was investigated in 22 hypertensive patients with gout in a randomized trial. All patients were treated with allopurinol and diet. A four weeks treatment with celiprolol (11 patients) showed no influence on uric acid metabolism, electrolytes, blood glucose, cholesterol and triglycerides. Under treatment with celiprolol plus chlorthalidone (11 patients) only a small rise in serum uric acid was observed after four weeks but at the same time uric acid clearance and excretion increased significantly. There was no obvious change in serum electrolytes but an increase in sodium, potassium and chloride urine excretion. Serum uric acid, uric acid clearance and excretion decreased during a 6 months treatment period. A small decrease in cholesterol and triglycerides was observed. Blood pressure decreased in both treatment groups but there was only a small change in heart rate.

Adrenergic beta-Antagonists↗

PubMed1977

[The urethrogram in children with neurogenic bladder dysfunction (author's transl)].

Various types of neurogenic bladder dysfunction in children show characteristic changes on micturating cystograms. The reflex bladder shows a short area of narrowing of the urethra at the pelvic floor; the autonomous bladder, during voiding by straining or Credé shows an elongated and deformed urethra, which is narrowed at the pelvic floor and which, because of the low position of the bladder, is angled. Both spastic and paretic pelvic floor in association with neurogenically determined abnormalities of bladder emptying may result in functional obstruction of the urethra. This, like any other stenosis, leads to morphological changes, first in the lower, but subsequently in the upper urinary tract. Children with neurogenic bladder dysfunction occasionally have micturating cystograms which resemble the appearances of urethral valves. The occurrence of so-called occult neurogenic bladders is mentioned and the difficulties in diagnosis associated with this condition are stressed.

Adolescent↗